Five manufacturers produced, authorized, and distributed COVID-19 vaccines fast enough to significantly reduce global deaths during the pandemic’s deadliest phase: Pfizer-BioNTech, Moderna, AstraZeneca, Sinovac, and Sinopharm. Together, their vaccines averted an estimated 17 million deaths in the first year of vaccination campaigns alone. But the full roster of major vaccine makers extends well beyond those five, spanning at least four distinct vaccine technologies and companies on every inhabited continent. Which ones you encountered depended heavily on where you lived.
The mRNA Makers
Pfizer-BioNTech and Moderna became the most recognized names in COVID vaccination, particularly in North America and Europe. Both companies built their vaccines on messenger RNA technology, which instructs cells to produce a piece of the SARS-CoV-2 spike protein so the immune system can learn to recognize it. The two vaccines encode identical spike protein sequences, but their internal components differ in ways that affect performance and handling.
The Pfizer-BioNTech vaccine, known as BNT162b2 (branded Comirnaty), was a collaboration between the German biotech firm BioNTech and the American pharmaceutical giant Pfizer. It uses modified RNA wrapped in tiny fat particles called lipid nanoparticles to deliver its payload into cells.1Prospects in Pharmaceutical Sciences. BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety Moderna’s vaccine, mRNA-1273 (branded Spikevax), uses a similar lipid nanoparticle approach but with a different ionizable lipid called SM-102. Comparative research found that SM-102 outperformed the lipid in the Pfizer-BioNTech vaccine for muscle-tissue delivery, antibody production in animal models, and long-term stability at refrigerator temperatures.2npj Vaccines. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
In practical terms, these differences translated into distinct logistics. The Pfizer-BioNTech vaccine originally demanded storage at around minus 70 degrees Celsius, requiring ultra-cold freezers that many clinics and low-income countries simply did not have. Each shipment consisted of trays holding 4,875 doses packed with dry ice.3PubMed Central. Management of COVID-19 vaccines cold chain logistics: a scoping review Moderna’s vaccine was more forgiving, stable at standard freezer temperatures for longer periods. This cold-chain gap shaped which vaccine went where during the critical early months of the rollout, when ultra-cold storage was a bottleneck in much of the world.
Viral Vector Vaccine Makers
A second wave of manufacturers used a different approach: viral vector vaccines. Instead of mRNA, these vaccines use a harmless adenovirus (a type of virus that normally causes common colds) to carry genetic instructions for the spike protein into cells. The major players in this category were AstraZeneca (partnered with the University of Oxford), Johnson & Johnson’s Janssen subsidiary (partnered with Beth Israel Deaconess Medical Center), Russia’s Gamaleya Research Institute, and China’s CanSino Biologics.4PubMed Central. Review of COVID-19 viral vector-based vaccines and COVID-19 variants
AstraZeneca’s vaccine, AZD1222 (branded Vaxzevria), became the workhorse of global vaccination efforts outside the United States. It was cheaper per dose than the mRNA vaccines and could be stored at normal refrigerator temperatures, making it far easier to distribute in low- and middle-income countries. AstraZeneca also committed early on to supplying vaccines at cost during the pandemic, which made it the backbone of the COVAX initiative that aimed to distribute doses equitably worldwide.
Johnson & Johnson’s vaccine (Ad26.COV2.S) had a distinct selling point: it was authorized as a single-dose regimen, while nearly every other early vaccine required two shots. Studies confirmed that a single dose followed by a booster increased antibody responses with an acceptable safety profile.5PubMed Central. Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan The one-dose convenience made it attractive for hard-to-reach populations and people unlikely to return for a second appointment. However, its use was later curtailed in the U.S. due to a rare blood-clotting side effect, and it was eventually pulled from the American market.
Russia’s Sputnik V, developed by the Gamaleya Research Institute, was the first COVID-19 vaccine to receive regulatory authorization anywhere in the world, though it did so before completing phase 3 trials, which drew early skepticism. It used two different adenovirus vectors for its two-dose series: one based on Ad26 for the first shot and Ad5 for the second.6PubMed Central. Sputnik V vaccine-related complications and its impression on inflammatory biomarkers in healthcare providers This “heterologous prime-boost” design was intended to reduce the chance that the body would mount an immune response against the vector itself after the first dose, potentially weakening the second dose. Sputnik V was used widely in Russia, parts of Latin America, Africa, and Asia, but it never gained authorization from the European Medicines Agency or the U.S. FDA, largely due to concerns about manufacturing consistency and transparency of trial data. CanSino’s Convidecia vaccine filled a similar niche in China and some other countries, also using a single-dose adenovirus vector approach.
Inactivated Virus Vaccine Makers
While mRNA and viral vector vaccines grabbed most headlines in Western media, inactivated virus vaccines quietly immunized billions of people across Asia, Latin America, the Middle East, and Africa. This technology is the most traditional of the COVID vaccine platforms: the actual SARS-CoV-2 virus is grown in cell culture, chemically killed so it can no longer replicate, and then injected to train the immune system. The major manufacturers were China’s Sinovac (CoronaVac), China’s Sinopharm (BBIBP-CorV), and India’s Bharat Biotech (Covaxin).
Sinovac’s CoronaVac was among the most widely administered vaccines globally by sheer dose count. A phase 3 trial in Turkey found it was about 84% effective at preventing symptomatic COVID-19 caused by earlier variants.7The Lancet. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey However, antibody levels after CoronaVac declined significantly after about 80 days and remained relatively low until a booster dose was given.8PubMed Central. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001) That faster antibody waning compared to mRNA vaccines became a practical issue as new variants emerged.
Sinopharm’s BBIBP-CorV, developed by the Beijing Institute of Biological Products, was the other Chinese inactivated vaccine distributed at massive scale, particularly through bilateral agreements with governments in the Middle East, North Africa, and Southeast Asia. Its performance against later variants told a sobering story, though. A real-world study in Mozambique during the Omicron wave found that two doses of the Sinopharm vaccine did not show statistically significant protection against symptomatic COVID-19, with adjusted effectiveness estimated at only around 18% and confidence intervals that crossed zero.9PubMed Central. Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique This pattern of sharply declining effectiveness against Omicron was not unique to Sinopharm; it highlighted a broader limitation of inactivated vaccines, which present the whole virus to the immune system rather than focusing on the spike protein, potentially generating a less targeted immune response.
India’s Bharat Biotech developed Covaxin (BBV152), the country’s homegrown inactivated vaccine. It used an inactivated whole-virion approach combined with an aluminum hydroxide gel adjuvant and a novel immune-boosting compound.10PubMed Central. Inactivated vaccine Covaxin/BBV152: A systematic review Covaxin played a major role in India’s vaccination drive alongside the AstraZeneca-derived Covishield, which was manufactured domestically by the Serum Institute of India.
Protein Subunit Vaccine Makers
Novavax took a different path from all the others. Its vaccine, NVX-CoV2373, is a recombinant protein subunit vaccine: instead of delivering genetic instructions for the spike protein and letting your cells build it, Novavax grows the spike protein in insect cells, purifies it, and packages it with a proprietary adjuvant called Matrix-M to amplify the immune response.11PubMed Central. The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century This is conceptually closer to how flu vaccines and hepatitis B vaccines have worked for decades, which made it appealing to people who were hesitant about the newer mRNA or viral vector technologies.
Novavax’s path to market was slow, plagued by manufacturing scale-up problems that delayed authorization well past the peak of global demand. By the time it became widely available, most eligible adults in wealthy countries had already received mRNA or viral vector vaccines. Still, Novavax carved out a niche as a booster option, particularly for people who experienced significant side effects from mRNA vaccines or who preferred a more established vaccine technology.12Vaccine. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373) It also had the practical advantage of stable refrigerator storage, unlike the original ultra-cold requirements for mRNA vaccines.
Which Five Saved the Most Lives
When researchers looked back at which manufacturers actually changed the trajectory of the pandemic, five stood out: AstraZeneca, Pfizer-BioNTech, Sinovac, Moderna, and Sinopharm. Together, their vaccines averted an estimated 17 million deaths in the first year of vaccination campaigns. The shared characteristic was not the technology they used, which spanned three distinct platforms, but their ability to rapidly scale production to the billions of doses needed.13Vaccine. How manufacturing won or lost the COVID-19 vaccine race Other vaccines that performed well in clinical trials but could not manufacture and distribute fast enough, including Novavax and some regional vaccines, arrived too late to meaningfully bend the global death curve.
This finding underscores something easy to overlook: the “best” vaccine in a pandemic is not necessarily the one with the highest efficacy in a controlled trial. It is the one that reaches arms fastest and in sufficient volume. AstraZeneca’s vaccine, often criticized for lower efficacy numbers than the mRNA shots, likely saved more lives worldwide than either Pfizer-BioNTech or Moderna simply because it was cheaper, easier to store, and distributed more broadly through programs like COVAX.
The COVAX Effort and Equity Gaps
COVAX, co-led by the World Health Organization, Gavi, and the Coalition for Epidemic Preparedness Innovations (CEPI), was the primary mechanism for getting vaccines to countries that could not compete with wealthy nations in direct purchase agreements. By January 2022, COVAX had allocated nearly 1.7 billion doses, distributing over a billion of those to 148 countries and territories.14PubMed Central. COVAX and equitable access to COVID-19 vaccines On paper, the program directed more doses per capita to the poorest countries through subsidized allocations. In practice, an equity gap persisted: wealthier countries that self-financed their COVAX doses received disproportionately more per capita, and the initiative consistently fell behind its own delivery targets.
The manufacturers most involved in COVAX supply were AstraZeneca (and its licensed producers like the Serum Institute of India), Pfizer-BioNTech, and Johnson & Johnson. The Chinese inactivated vaccines also reached many low-income countries, though mostly through bilateral government-to-government deals rather than COVAX. The result was a patchwork: people in wealthy nations generally received mRNA vaccines, while much of Africa, South Asia, and Latin America received inactivated or viral vector vaccines with different effectiveness profiles.
Government Funding Behind the Scenes
No COVID vaccine maker operated without substantial government support, but the scale varied enormously. The United States’ Operation Warp Speed program provided roughly $18 billion in funding for vaccine development, manufacturing, and advance purchases.15PubMed Central. Operation Warp Speed: implications for global vaccine security This funding did not just support clinical trials. It underwrote the massive financial risk of manufacturing hundreds of millions of doses before anyone knew whether the vaccines would work. Moderna, in particular, received extensive U.S. government funding from its earliest development stages through the National Institutes of Health, which co-developed the vaccine’s spike protein design.
Pfizer took a slightly different approach, funding its own clinical trials but accepting a large advance purchase commitment from the U.S. government, which effectively guaranteed a market. AstraZeneca received heavy support from the UK government and European Union. Russia funded Sputnik V through state institutions, and China’s government backed both Sinovac and Sinopharm as state-linked enterprises. The line between “private” and “public” vaccine development was effectively nonexistent during the pandemic. Even for companies that touted their independence from government subsidies, public funding of basic mRNA research over the preceding decade laid the scientific groundwork.
How Variant Updates Changed the Landscape
The original vaccines were designed against the ancestral Wuhan strain of SARS-CoV-2, and as the virus evolved, their effectiveness against infection (though not against severe disease) dropped. This forced vaccine makers to adapt. Pfizer-BioNTech and Moderna both developed bivalent boosters targeting Omicron subvariants alongside the original strain. In a phase 2-3 trial, Moderna’s bivalent booster (targeting the original strain plus Omicron BA.1) produced higher neutralizing antibody levels against BA.1 and BA.4/BA.5 than the original booster formula.16PubMed Central. A Bivalent Omicron-Containing Booster Vaccine against Covid-19 Similarly, bivalent boosters targeting BA.4/BA.5 outperformed the original monovalent booster for Omicron-specific neutralization.17PubMed Central. Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
This pattern of periodic strain updates now mirrors the annual flu vaccine model, where manufacturers reformulate each year based on circulating variants. The mRNA platform proved particularly well suited to this because updating the vaccine requires changing only the genetic sequence rather than growing a new virus, which is faster and cheaper. Viral vector and inactivated vaccine makers found it harder to pivot quickly, which contributed to the mRNA companies further consolidating their dominance in wealthy-country markets. By 2024, annual COVID boosters in most Western nations were exclusively mRNA-based, produced by Pfizer-BioNTech or Moderna, with Novavax maintaining a smaller protein-based alternative.
Mucosal Vaccines and the Next Generation
All of the vaccines discussed so far are injected into muscle, which generates strong systemic immunity (antibodies circulating in the blood) but relatively weak mucosal immunity in the nose, throat, and lungs where SARS-CoV-2 actually enters. This is one reason vaccinated people could still catch and transmit the virus even when protected from severe illness. A growing number of researchers and manufacturers are working on mucosal vaccines, delivered as nasal sprays or inhaled mists, designed to provoke immune defenses right at the point of viral entry.
Preclinical and early clinical trials have shown that mucosal COVID vaccines can trigger secretory IgA antibodies and tissue-resident memory cells in the respiratory tract, reducing not just disease but also viral replication and transmission.18Vaccine. A review of currently licensed mucosal COVID-19 vaccines Several countries have already authorized mucosal COVID vaccines: China and India approved inhaled or intranasal versions for booster use. One experimental approach combined COVID and influenza protection in a single intranasal vaccine using a chimpanzee adenovirus vector, which in animal studies induced both IgG and mucosal IgA antibodies and protected against both infections.19npj Vaccines. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza
Combination vaccines that protect against COVID and flu in one shot or one spray represent the frontier that several companies are racing toward. If these prove effective in large human trials, the roster of “main COVID vaccine makers” could look quite different in a few years, with companies currently known for flu vaccines entering the space and the distinction between seasonal respiratory vaccines blurring. For now, the field remains dominated by the companies that won the original pandemic manufacturing race, but the technology they proved viable, particularly mRNA lipid nanoparticle delivery, has spawned dozens of competitors and offshoots that are reshaping vaccine development far beyond COVID.20PubMed Central. Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters